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Objective: To establish guidelines based on scientiﬁc evidence for the management of famil-
ial  Mediterranean fever.
Description of the evidence collection method: The Guideline was prepared from 5 clinical ques-
tions that were structured through PICO (Patient, Intervention or indicator, Comparison
and Outcome), to search key primary scientiﬁc information databases. After deﬁning the
potential studies to support the recommendations, these were graduated considering theiramilial Mediterranean fever
uidelines
hildhood
strength of evidence and grade of recommendation.
Results: 10,341 articles were retrieved and evaluated by title and abstract; from these,
46  articles were selected to support the recommendations.
∗ Corresponding author.
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Fever
Autoinﬂammatory syndromes
Recommendations: 1. The diagnosis of FMF is based on clinical manifestations, character-
ized  by recurrent febrile episodes associated with abdominal pain, chest or arthritis of large
joints. 2. FMF is a genetic disease presenting an autosomal recessive trait, caused by muta-
tion in the MEFV gene. 3. Laboratory tests are not speciﬁc, demonstrating high serum levels
of  inﬂammatory proteins in the acute phase of the disease, but also often showing high
levels even between attacks. SAA serum levels may be especially useful in monitoring the
effectiveness of treatment. 4. The therapy of choice is colchicine; this drug has proven its
effectiveness in preventing acute inﬂammatory episodes and progression toward amyloid-
osis in adults. 5. Based on the available information, the use of biological drugs appears to
be an alternative for patients with FMF who do not respond or are intolerant to therapy with
colchicine.
©  2015 Elsevier Editora Ltda. All rights reserved.
Diretrizes  de  conduta  e  tratamento  de  síndromes  febris  periódicas
associadas  a  febre  familiar  do  Mediterrâneo
Palavras-chave:
Febre familiar do Mediterrâneo
Diretrizes
Infância
Febre
Síndromes autoinﬂamatórias
r  e  s  u  m  o
Objetivo: Estabelecer diretrizes baseadas em evidências cientíﬁcas para manejo da Febre
Familiar do Mediterrâneo (FFM).
Descric¸ão do método de coleta de evidência: A Diretriz foi elaborada a partir de 5 questões
clínicas que foram estruturadas por meio do P.I.C.O. (Paciente, Intervenc¸ão ou Indicador,
Comparac¸ão  e Outcome), com busca nas principais bases primárias de informac¸ão cientíﬁca.
Após deﬁnir os estudos potenciais para sustento das recomendac¸ões, estes foram graduados
pela  forc¸a da evidência e grau de recomendac¸ão.
Resultados: Foram recuperados, e avaliados pelo título e resumo, 10.341 trabalhos, tendo
sido  selecionados 46 artigos para sustentar as recomendac¸ões.
Recomendac¸ões: 1. O diagnóstico da FFM é baseado nas manifestac¸ões clínicas, caracterizadas
por  episódios febris recorrentes associados a dor abdominal, torácica ou artrite de grandes
articulac¸ões;  2. A FFM é uma doenc¸a genética apresentando trac¸o autossômico recessivo
ocasionada por mutac¸ão no gene MEFV; 3. Exames laboratoriais são inespecíﬁcos demon-
strando níveis séricos elevados de proteínas inﬂamatórias na fase aguda da doenc¸a, mas
também, com frequência, demonstrando níveis elevados mesmo entre os ataques. Níveis
séricos de SAA podem ser especialmente úteis no monitoramento da eﬁcácia do tratamento;
4.  A colchicina é a terapia de escolha tendo demonstrado eﬁcácia na prevenc¸ão dos episódios
inﬂamatórios agudos e progressão para amiloidose em adultos; 5. Com base na informac¸ão
disponível, a utilizac¸ão de medicamentos biológicos parece ser alternativa para pacientes
com FFM que não respondem ou que são intolerantes à terapia com colchicina.
©  2015 Elsevier Editora Ltda. Todos os direitos reservados.Introduction
Periodic fever syndromes are autoinﬂammatory syndromes
and are a group of diseases clinically characterized by recur-
rent or continuous fever and systemic inﬂammation, lasting
from a few days to several weeks, with intervals without
symptoms that may vary in their duration. The presence of
crises of predictable development in association with a sim-
ilar family history may suggest a periodic fever syndrome.
Recent advances in the understanding of the molecular
basis of inﬂammation mechanisms allowed the identiﬁ-
cation of genetic alterations involved in the pathogenesis
of these diseases. Currently, the following syndromes aredescribed: familial Mediterranean fever, hyperimmunoglob-
ulinemia D syndrome (HIDS), tumor necrosis factor (TNF)
alpha receptor-associated periodic syndrome (TRAPS), peri-
odic fever, aphthous stomatitis, pharyngitis and adenitis
(PFAPA) syndrome, and cryopyrinopathies which include three
syndromes: Muckle–Wells syndrome (MWS), familial cold-
associated urticaria (FCU) and chronic infantile neurological,
cutaneous and articular (CINCA) syndrome. Due  to their clin-
ical relevance, the Pediatric Rheumatology Commission of
the Brazilian Society of Rheumatology selected three peri-
odic fever syndromes and developed Brazilian Guidelines for
the conduct and treatment of familial Mediterranean fever,
cryopyrinopathies, and periodic fever, aphthous stomatitis,
pharyngitis and adenitis syndrome.
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amilial  Mediterranean  fever
escription  of  the  method  of  evidence  collection
he Guideline was prepared from 5 relevant clinical ques-
ions related to the management of familial Mediterranean
ever (FMF). The questions were structured by the use of
ICO (Patient, Intervention or indicator, Comparison and Out-
ome), allowing the generation of strategies for searching
vidence (described after each question, with the number
f recovered articles), in the main primary databases of sci-
ntiﬁc information (Medline/Pubmed, Embase, Lilacs/Scielo,
ochrane Library). The recovered evidence has been selected
rom a critical evaluation using discriminatory instruments
scores): JADAD and GRADE for Randomized Clinical Trials, and
ew Castle Ottawa scale for observational studies. After deﬁn-
ng the potential studies to support the recommendations,
hese articles were rated based on the strength of evidence
nd grade of recommendation, according to the classiﬁcation
f Oxford (available at www.cebm.net), including available evi-
ence of greatest strength.
ummary  of  grades  of  recommendation  and  strength
f evidence
A: Experimental or observational studies of higher consis-
tency
B: Experimental or observational studies of lower consis-
tency
C: Case reports (noncontrolled studies).
D: Expert opinion without explicit critical appraisal, or
based on physiology or bench research.
bjective
o establish guidelines based on scientiﬁc evidence for the
anagement of familial Mediterranean fever (FMF).
1. When should we suspect that an individual is a carrier of
familial Mediterranean fever?
trategy
Familial Mediterranean Fever OR Familial Mediterranean
ever, Autosomal Recessive OR Familial Paroxysmal Poly-
erositis OR Familial Paroxysmal Polyserositides OR Parox-
smal Polyserositides, Familial OR Paroxysmal Polyserositis,
amilial OR Polyserositides, Familial Paroxysmal OR Mediter-
anean Fever, Familial OR Periodic Disease OR Periodic
iseases OR Wolff’s Periodic Disease OR Periodic Peritonitis OR
eriodic Peritonitides OR Peritonitis, Periodic OR Polyserositis,
amilial Paroxysmal OR Polyserositis, Recurrent) AND Signs
nd Symptoms. n = 2518.
The diagnostic suspicion of familial Mediterranean fever
FMF) is based on clinical manifestations, which are character-
zed by recurrent febrile episodes associated with abdominal
nd/or chest pain caused by serositis (peritonitis, pericarditis
r pleurisy) and arthritis/synovitis of large joints, accompa-
ied by erysipeloid erythema, whose emergence, in most 0 1 6;5  6(1):37–43 39
patients, occurs before the age of 30 (60 and 90% before 10 and
20 years old, respectively)1,2 (D). The episodes have short dura-
tion (1–3 days) with resolution occurring even in the absence
of treatment; the periodicity is irregular, varying from once a
week to once a year. Between attacks, patients remain asymp-
tomatic. Mediterranean region ancestry is a frequent ﬁnding.
The attacks can be triggered by emotional stress, intense
physical activity, temperature extremes, viral infection, or
even menstruation. The disease usually occurs along with the
symptoms of peritonitis and arthritis. However, it may man-
ifest atypically, with only isolated episodes of sudden onset
of fever with spontaneous resolution in the absence of signs
of serositis3 (B)4,5 (D). Patients with FMF  may also present
nonspeciﬁc signs and symptoms mimicking infection, acute
appendicitis, cholecystitis and arthritis, which may delay the
establishment of the deﬁnitive diagnosis.
Abdominal pain is the most common feature of FMF,  occur-
ring in around 95% of patients. It may be diffuse or localized,
being mild to severe in terms of intensity. Joint involvement
is the second most common manifestation. In most cases the
arthritis has an acute onset and affects large joints of lower
limbs and can last longer than the other manifestations of
the disease. Monoarthritis may be the only manifestation of a
crisis in 75% of cases.6 Pain and swelling in the scrotum may
occur in preschool children. The most important long-term
complication is secondary amyloidosis (AA type)4 (D).
Recommendation
The diagnosis of FMF is based on clinical manifestations,
characterized by recurrent febrile episodes associated with
abdominal and chest pain, or arthritis of large joints.
2. How one determines the genetic diagnosis of familial Mediter-
ranean fever?
Strategy
(Familial Mediterranean Fever OR Familial Mediterranean
Fever, Autosomal Recessive OR Familial Paroxysmal Poly-
serositis OR Familial Paroxysmal Polyserositides OR  Parox-
ysmal Polyserositides, Familial OR Paroxysmal Polyserositis,
Familial OR Polyserositides, Familial Paroxysmal OR Mediter-
ranean Fever, Familial OR Periodic Disease OR Periodic
Diseases OR Wolff’s Periodic Disease OR Periodic Peritonitis OR
Periodic Peritonitides OR Peritonitis, Periodic OR Polyserositis,
Familial Paroxysmal OR Polyserositis, Recurrent) AND (Diag-
nosis[ﬁlter]). n = 705.
FMF  is classiﬁed as a hereditary periodic fever syndrome7
(D). It was ﬁrst described in 1945, being known under the
name of “benign paroxysmal peritonitis”8 (D). This is a genetic
autoinﬂammatory disease with an autosomal recessive trait,
caused by a mutation in the MEFV gene (Mediterranean fever
gene) located on the short arm of chromosome 16 (16p13) and
encoding a protein composed of 781 amino acids named pyrin
or marenostrin. Apparently, this protein plays a critical role in
regulating the inﬂammatory process (modulating interleukin
9,10production) and apoptosis (D). At least 299 mutations have
been described, many  of which occur in exon 10 (the great-
est in this gene), where one can identify the four primary
mutations in the majority of patients with FMF: M694V, V726A,
 t o l .40  r e v b r a s r e u m a
M680I and M694I11 (D). The mutation p.Met694V relates to the
more  severe form of the disease, conferring a high risk for
occurrence of amyloidosis12 (C)13 (B). However, there is no lin-
earity in genotype–phenotype correlation, with great diversity
in clinical expression of patients’ carriers of the same muta-
tion in the MEFV gene14 (C).
The presence of two mutations leading to a homozygous
state is found in 60% of subjects, and in 10% a mutation was
not identiﬁed3 (B). However, 30% of patients with a typical
clinical presentation of FMF  show only a single mutation. An
evaluation of a population sample identiﬁed that the num-
ber of individuals with the doubly mutated and not expressed
MEFV gene exceeds the number of patients with a diagnosis
of FMF.  This fact, coupled with the phenotypic variability of
FMF,  suggests an important role of environmental factors on
the clinical expression of FMF15,16 (B).
Recommendation
FMF  is a genetic disease presenting an autosomal recessive
trait, and caused by a mutation in the MEFV gene. A more
severe disease with high risk for amyloidosis can be seen in
patients with p.Met694V mutation, revealing the potential of
a genotype–phenotype correlation. Mutations and polymor-
phisms in genes other than MEFV may have an impact on the
development of FMF,  or even on the severity of the disease.
3. Besides genetic studies, what tests should be required for the
evaluation of patients with familial Mediterranean fever?
Strategy
(Familial Mediterranean Fever OR Familial Mediterranean
Fever, Autosomal Recessive OR Familial Paroxysmal Poly-
serositis OR Familial Paroxysmal Polyserositides OR Parox-
ysmal Polyserositides, Familial OR Paroxysmal Polyserositis,
Familial OR Polyserositides, Familial Paroxysmal OR Mediter-
ranean Fever, Familial OR Periodic Disease OR Periodic
Diseases OR Wolff’s Periodic Disease OR Periodic Peritonitis OR
Periodic Peritonitides OR Peritonitis, Periodic OR Polyserositis,
Familial Paroxysmal OR Polyserositis, Recurrent) AND (Diag-
nosis/Broad[ﬁlter]). n = 6126.
Crises related to FMF are characterized by leukocytosis and
high levels of acute phase proteins, for instance, erythrocyte
sedimentation rate (ESR), C-reactive protein (CRP), ﬁbrino-
gen, haptoglobulin, C3 and C4 fractions of complement, and
serum amyloid A protein (SAA)17 (C). These inﬂammatory
markers help the physician to distinguish FMF-related crises
from other diseases such as viral infection, ﬁbromyalgia and
irritable bowel syndrome. A persistently high SAA leads to
higher probability of developing amyloidosis. Proteinuria, as
an indicator of renal amyloidosis, develops years after the
onset of an untreated FMF,  constituting a late complication.
In patients with severe or uncontrolled disease, the levels of
acute phase proteins may remain high in the interval between
episodes18 (C).Recommendation
Laboratory tests are not speciﬁc, with high serum levels of
inﬂammatory proteins in the acute phase of this disease, but 2 0 1 6;5 6(1):37–43
often, high levels are found even between attacks. SAA levels
may be particularly useful in monitoring the effectiveness of
treatment.
4. What is the role of colchicine in the treatment of familial
Mediterranean fever?
Strategy
(Familial Mediterranean Fever OR Familial Mediterranean
Fever, Autosomal Recessive OR Familial Paroxysmal Poly-
serositis OR Familial Paroxysmal Polyserositides OR Parox-
ysmal Polyserositides, Familial OR Paroxysmal Polyserositis,
Familial OR Polyserositides, Familial Paroxysmal OR Mediter-
ranean Fever, Familial OR Periodic Disease OR Periodic
Diseases OR Wolff’s Periodic Disease OR Periodic Peritonitis OR
Periodic Peritonitides OR Peritonitis, Periodic OR Polyserosi-
tis, Familial Paroxysmal OR Polyserositis, Recurrent) AND
Colchicine AND (Therapy/Broad[ﬁlter]). n = 696.
Colchicine is a tricyclic alkaloid extracted from plants
belonging to Colchicum and Gloriosa genera. This was the ﬁrst
microtubule destabilizing agent identiﬁed, showing antipro-
liferative activity19 (D). Over the past 50 years, colchicine has
been used in an increasing number of diseases, including FMF,
Behcet’s syndrome, scleroderma and amyloidosis.
Studies have demonstrated that colchicine inhibits the
synthesis of TNF, leukotriene B4, cyclooxygenase 2 activity,
prostaglandin E2, and thromboxane A220,21 (D). In mono-
cytes, colchicine reaches higher concentrations than the levels
present in the plasma, and their levels are dependent on gly-
coprotein P. This feature makes it difﬁcult to predict, based on
plasma levels, the concentration of colchicine which can be
achieved in inﬂammatory cells, and also explains the lack of
response by some patients with FMF, due to the polymorphism
of the gene encoding P-glycoprotein. Studies have shown that
daily administration of colchicine prevents both the inﬂam-
matory attacks and the occurrence of secondary amyloidosis,
a major long-term complication of FMF. While most anti-
inﬂammatory effects of colchicine are related to the disruption
of microtubule function, with inhibition of chemotaxis of neu-
trophils and suppression of inﬂammation, effects on NLRP3
inﬂammasome activity in macrophages and in the produc-
tion and maturation of cytokines from dendritic cells have also
been observed22 (C)23 (D).
The most effective results have been obtained using
colchicine for FMF prophylaxis; in such patients, this agent
prevented the occurrence of episodes of acute inﬂamma-
tion and also the development of amyloidosis24–26 (B)27 (C).
Three crossover clinical trials have demonstrated efﬁcacy
of colchicine by decreasing the recurrence of inﬂammatory
episodes. One study identiﬁed that, among 43 patients, the
number of inﬂammatory episodes fell from 178 during the use
of placebo to 29 with the administration of colchicine. In this
study, their authors observed a signiﬁcant fall in the severity
of attacks, since 70% of the episodes were considered mild,
26compared to only 25% with the use of placebo (B).
However, this treatment did not show efﬁcacy in the con-
trol of acute attacks, when administered early during the
episodes28 (C).
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Although colchicine cannot completely prevent febrile
pisodes, its use may halt the progression of amyloidosis,
eversing proteinuria in the absence of irreversible glomerular
amage29 (C). One study showed that proteinuria development
ate after a period of 9–11 years was 1.7% in 960 adult patients
ho  have made a proper use of colchicine versus 49% in
4 patients who did not properly use the drug24 (B). Among
he 86 patients without proteinuria at nephrotic levels before
he introduction of colchicine, this drug promoted resolution
n ﬁve patients and stabilization of proteinuria in 6824 (B).
ecommendation
olchicine is the therapy of choice; this drug showed efﬁcacy
n preventing acute inﬂammatory episodes and progression
oward amyloidosis in adults.
5. What is the role of biological agents in the treatment of familial
Mediterranean fever?
trategy  (FMF  IL-1  receptor  antagonist)
Familial Mediterranean Fever OR Familial Mediterranean
ever, Autosomal Recessive OR Familial Paroxysmal Poly-
erositis OR Familial Paroxysmal Polyserositides OR Parox-
smal Polyserositides, Familial OR Paroxysmal Polyserositis,
amilial OR Polyserositides, Familial Paroxysmal OR Mediter-
anean Fever, Familial OR Periodic Disease OR Periodic
iseases OR Wolff’s Periodic Disease OR Periodic Peritonitis OR
eriodic Peritonitides OR Peritonitis, Periodic OR Polyserosi-
is, Familial Paroxysmal OR Polyserositis, Recurrent) AND
Interleukin 1 Receptor Antagonist Protein OR Anakinra OR
rine-Derived IL1 Inhibitor OR IL1 Inhibitor, Urine-Derived OR
rine Derived IL1 Inhibitor OR IL1 Febrile Inhibitor OR Febrile
nhibitor, IL1) AND (Therapy/Broad[ﬁlter]). n = 113.
trategy  (FMF  and  anti-TNF  agents)
Familial Mediterranean Fever OR Familial Mediterranean
ever, Autosomal Recessive OR Familial Paroxysmal Poly-
erositis OR Familial Paroxysmal Polyserositides OR Parox-
smal Polyserositides, Familial OR Paroxysmal Polyserositis,
amilial OR Polyserositides, Familial Paroxysmal OR Mediter-
anean Fever, Familial OR Periodic Disease OR Periodic
iseases OR Wolff’s Periodic Disease OR Periodic Peritonitis OR
eriodic Peritonitides OR Peritonitis, Periodic OR Polyserosi-
is, Familial Paroxysmal OR Polyserositis, Recurrent) AND
inﬂiximab OR etanercept OR adalimumab OR golimumab OR
ertolizumab OR Tumor Necrosis Factor alpha OR Cachectin-
umor Necrosis Factor OR Cachectin Tumor Necrosis Factor
R TNF alpha OR TNF-alpha OR Tumor Necrosis Factor OR
umor Necrosis Factor Ligand Superfamily Member 2) AND
Therapy/Broad[ﬁlter]). n = 183.
L-1  receptor  antagonists
arriers of FMF  show signiﬁcantly elevated levels of serum
30NF, IL-1, IL-6 and IL-8 (B). Evidence has demonstrated
n important role of pyrin in the regulation of caspase-1 acti-
ation and subsequent cleavage of the interleukin precursor
n its biologically active form (pyrin binds procaspase-1, acti- 0 1 6;5  6(1):37–43 41
vating caspase-1, which cleaves pro-IL-1 to its active form)31
(D). Thus, as elevated levels of IL-1 are related to inﬂamma-
tory activity, some authors proposed the use of drugs targeting
interleukin 1 (IL-1), a proinﬂammatory cytokine.
The use of IL-1 receptor antagonists in patients with
FMF has been described in the following situations:
patients with incomplete control of disease activity despite
treatment with colchicine (5–10% may be resistant to
colchicine); patients with maintenance of high serum levels
of SAA, inability to use colchicine because of serious adverse
effects, and in cases of disease associated to vasculitis32–35 (C).
Three different types of IL-1 receptor antagonists are available:
anakinra is a human recombinant unglycosylated analog of
the IL-1 receptor antagonist (rhIL-1Ra); rilonacept is a fusion
protein that contains the extracellular portions of type I IL-1
receptor and IL-1 receptor accessory protein.
Anakinra and rilonacept target IL-1 and IL-1; anakinra
acts by binding to IL-1 receptor type I, inhibiting its biological
effects, and rilonacept neutralizes IL-1 in blood circulation. On
the other hand, canakinumab, a fully humanized monoclonal
antibody of the class IgG1, acts speciﬁcally against IL-136 (D).
A review conducted in MEDLINE primary database via
PubMed could only identify case reports as evidence available
to evaluate the effectiveness of IL-1 receptor antagonists in
patients with a diagnosis of FMF. One has to consider that, in
this kind of study, only positive results tend to be reported.
In these studies, treatment with anakinra (children: 1 mg/kg
in children; adults; 100 mg/day) or canakinumab (children
under 40 kg: 2 mg/kg every eight weeks; adults: 150 mg  every
eight weeks) showed beneﬁcial results, indicating that drugs
targeted to IL-1 receptor antagonism can be good choices
when one seeks an additional or alternative treatment for
colchicine37–41 (C). As to the safety of these drugs, pain and
signs of inﬂammation at the injection site were the only
adverse events reported during the administration of anakinra
and canakinumab.
Despite the uncertainty related to the use of IL-1 recep-
tor antagonists in the treatment of patients with FMF,  these
agents appear to be viable therapeutic alternatives for patients
intolerant or unresponsive to the use of colchicine, as well as
for those with renal impairment or elevated levels of SAA, even
when taking colchicine.
Anti-TNF  agents
The role of tumor necrosis factor  (TNF-)  in the patho-
genesis of FMF is not yet clearly deﬁned, but there is some
evidence with respect to its clinical manifestations. Serum
levels of TNF- are increased during recurrences of attacks;
and decreases in serum levels of TNF- have been observed in
patients under regular treatment with colchicine42 (D)30,43 (C).
Thus, the use of drugs binding to circulating TNF- molecules
or attaching to the surface of effector cells, inhibiting binding
to their receptor, thus obviating the biological effects of TNF-,
may be an alternative for patients with FMF44 (C).Studies on the use of anti-TNF agents such as adalimumab,
inﬂiximab, and etanercept in patients (mean age: 30 years)
diagnosed with FMF and who presented chronic arthritis with
or without sacroiliitis as clinical manifestation and that were
 t o l .
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resistant to treatment with colchicine, identiﬁed, after a mean
follow-up of 28 (±18) months, a lower frequency of relapses45
(C). Recently, a review study conducted in MEDLINE primary
database via PubMed found only case reports and case series
of patients diagnosed with FMF  under treatment with bio-
logic drugs, making a total of 59 patients, of which 25 had
been treated with anti-TNF agents (etanercept, inﬂiximab, or
adalimumab)46 (B). Despite the clinical improvement identi-
ﬁed among patients with arthritis and/or spondylitis, more
robust evidence arising from well-designed clinical trials is
needed to evaluate the efﬁcacy and safety of these drugs.
Recommendation
Current data on the use of biological drugs in the treatment
of FMF  are limited to case reports or case series, and therefore
it is a hard task to obtain a quantitative assessment of treat-
ment responses. Based on available information, the use of
biologicals appears to be an alternative for patients with FMF
nonresponders or intolerant to colchicine. More  controlled
studies are needed to evaluate the efﬁcacy and safety of this
strategy.
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